Adela CaÃ±ete Nieto

List of Publications by Year
in descending order

78 papers	2,607 citations	236925 25 h-index	206112 48 g-index
82 all docs	82 docs citations	82 times ranked	3898 citing authors

#	Article	IF	Citations
1	High Oct4 expression: implications in the pathogenesis of neuroblastic tumours. BMC Cancer, 2019, 19, 1.	2.6	420
2	Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncology, The, 2017, 18, 500-514.	10.7	256
3	Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncology, The, 2009, 10, 663-671.	10.7	176
4	Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer, 1995, 75, 99-109.	4.1	159
5	Excellent Outcome With Reduced Treatment for Infants With Disseminated Neuroblastoma Without MYCN Gene Amplification. Journal of Clinical Oncology, 2009, 27, 1034-1040.	1.6	134
6	Poor Survival for Infants With MYCN-Amplified Metastatic Neuroblastoma Despite Intensified Treatment: The International Society of Paediatric Oncology European Neuroblastoma Experience. Journal of Clinical Oncology, 2009, 27, 1014-1019.	1.6	123
7	Excellent Outcome With Reduced Treatment in Infants With Nonmetastatic and Unresectable Neuroblastoma Without MYCN Amplification: Results of the Prospective INES 99.1. Journal of Clinical Oncology, 2011, 29, 449-455.	1.6	101
8	Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma. Journal of Clinical Oncology, 2018, 36, 951-958.	1.6	95
9	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precision Oncology, 2020, 4, 561-571.	3.0	62
10	Risk stratification of highâ€risk metastatic neuroblastoma: A report from the HRâ€NBLâ€1/SIOPEN study. Pediatric Blood and Cancer, 2018, 65, e27363.	1.5	53
11	Targeting Neuroblastoma Stem Cells with Retinoic Acid and Proteasome Inhibitor. PLoS ONE, 2013, 8, e76761.	2.5	52
12	Disialoganglioside GD2 anti-idiotypic monoclonal antibodies. International Journal of Cancer, 1993, 54, 499-505.	5.1	48
13	miRâ€200c and phosphoâ€AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis. Molecular Oncology, 2016, 10, 1043-1053.	4.6	44
14	Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study. Cancers, 2019, 11, 1476.	3.7	43
15	The Doublecortin Gene, A New Molecular Marker to Detect Minimal Residual Disease in Neuroblastoma. Diagnostic Molecular Pathology, 2005, 14, 53-57.	2.1	41
16	Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study. Neuro-Oncology, 2013, 15, 1236-1243.	1.2	41
17	PRIMAGE project: predictive in silico multiscale analytics to support childhood cancer personalised evaluation empowered by imaging biomarkers. European Radiology Experimental, 2020, 4, 22.	3.4	41
18	Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease. Molecular Carcinogenesis, 2011, 50, 153-162.	2.7	39

#	Article	IF	Citations
19	Advances in emerging drugs for the treatment of neuroblastoma. Expert Opinion on Emerging Drugs, 2017, 22, 63-75.	2.4	36
20	Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition. Clinical Cancer Research, 2017, 23, 6875-6887.	7.0	34
21	MYCN gain and MYCN amplification in a stage 4S neuroblastoma. Cancer Genetics and Cytogenetics, 2003, 140, 157-161.	1.0	30
22	Vitronectin as a molecular player of the tumor microenvironment in neuroblastoma. BMC Cancer, 2019, 19, 479.	2.6	30
23	Solid ovarian tumours in childhood: a 35-year review in a single institution. Clinical and Translational Oncology, 2010, 12, 287-291.	2.4	29
24	Neuroblastoma in adolescents: genetic and clinical characterisation. Clinical and Translational Oncology, 2010, 12, 49-54.	2.4	28
25	TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients. Journal of Cancer Research and Clinical Oncology, 2016, 142, 573-580.	2.5	28
26	Two independent epigenetic biomarkers predict survival in neuroblastoma. Clinical Epigenetics, 2015, 7, 16.	4.1	26
27	Neuroblastoma after Childhood: Prognostic Relevance of Segmental Chromosome Aberrations, ATRX Protein Status, and Immune Cell Infiltration. Neoplasia, 2014, 16, 471-480.	5.3	25
28	Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 419-426.	2.1	20
29	Treatment of high-risk neuroblastoma with anti-GD2 antibodies. Clinical and Translational Oncology, 2010, 12, 788-793.	2.4	20
30	Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric Blood and Cancer, 2019, 66, e27819.	1.5	20
31	Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1263-1272.	2.5	19
32	Congenital Fibrosarcoma Simulating Congenital Hemangioma. Pediatric Dermatology, 2008, 25, 141-144.	0.9	18
33	Quantitative modeling of clinical, cellular, and extracellular matrix variables suggest prognostic indicators in cancer: a model in neuroblastoma. Pediatric Research, 2014, 75, 302-314.	2.3	17
34	A comparison of current neuroblastoma chemotherapeutics. Expert Opinion on Pharmacotherapy, 2004, 5, 71-80.	1.8	16
35	Herpesvirus-6 Encephalitis Complicated by Wernickeâ€“Korsakoff Syndrome in a Pediatric Recipient of Unrelated Cord Blood Transplantation. The American Journal of Pediatric Hematology/oncology, 2001, 23, 626-628.	1.3	15
36	MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors. Journal of Cancer Research and Clinical Oncology, 2009, 135, 523-531.	2.5	15

#	Article	IF	Citations
37	TIAM1 variants improve clinical outcome in neuroblastoma. Oncotarget, 2017, 8, 45286-45297.	1.8	15
38	Clinical Features of Neuroblastoma with 11q Deletion: An Increase in Relapse Probabilities in Localized and 4S Stages. Scientific Reports, 2019, 9, 13806.	3.3	15
39	Retained intravascular fragments after removal of indwelling central venous catheters: a single institution experience. Journal of Pediatric Surgery, 2010, 45, 1491-1495.	1.6	14
40	Analysis of biological prognostic factors using tissue microarrays in neuroblastic tumors. Pediatric Blood and Cancer, 2009, 52, 209-214.	1.5	12
41	MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial. Radiology, 2022, 304, 174-182.	7.3	12
42	Review: Ewing Sarcoma Predisposition. Pathology and Oncology Research, 2020, 26, 2057-2066.	1.9	11
43	A Novel TP53 Germ-Line Mutation Identified in a Girl with a Primitive Neuroectodermal Tumor and Her Father. Cancer Genetics and Cytogenetics, 1998, 105, 103-108.	1.0	10
44	Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial. Clinical Cancer Research, 2020, 26, 1856-1865.	7.0	10
45	MR Denoising Increases Radiomic Biomarker Precision and Reproducibility in Oncologic Imaging. Journal of Digital Imaging, 2021, 34, 1134-1145.	2.9	10
46	MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients. International Journal of Molecular Sciences, 2020, 21, 2714.	4.1	9
47	Unraveling the extracellular matrix-tumor cell interactions to aid better targeted therapies for neuroblastoma. International Journal of Pharmaceutics, 2021, 608, 121058.	5.2	9
48	Presentation and Long-term Outcome of High-grade Osteosarcoma. Journal of Pediatric Hematology/Oncology, 2015, 37, e272-e277.	0.6	8
49	Management and outcome of children and adolescents with non-medulloblastoma CNS embryonal tumors in Spain: room for improvement in standards of care. Journal of Neuro-Oncology, 2018, 137, 205-213.	2.9	8
50	Tumour banks in pediatric oncology. Clinical and Translational Oncology, 2006, 8, 884-888.	2.4	7
51	Prognostic value of partial genetic instability in neuroblastoma with â‰¥50% neuroblastic cell content. Histopathology, 2011, 59, 22-30.	2.9	7
52	New prognostic markers in neuroblastoma. Expert Opinion on Medical Diagnostics, 2012, 6, 555-567.	1.6	7
53	Eventâ€free survival of infants and toddlers enrolled in the HRâ€NBLâ€1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis. Pediatric Blood and Cancer, 2018, 65, e27052.	1.5	7
54	Staging childhood cancers in Europe: Application of the Toronto stage principles for neuroblastoma and Wilms tumour. The JARC pilot study. Pediatric Blood and Cancer, 2021, 68, e29020.	1.5	7

#	Article	IF	Citations
55	Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care. Cancers, 2021, 13, 5339.	3.7	7
56	Multimodality Treatment of Pediatric and Adult Patients With Ewing Sarcoma. Journal of Pediatric Hematology/Oncology, 2015, 37, e278-e284.	0.6	6
57	A Confidence Habitats Methodology in MR Quantitative Diffusion for the Classification of Neuroblastic Tumors. Cancers, 2020, 12, 3858.	3.7	6
58	Metabolomic profiling in neuroblastoma. Pediatric Blood and Cancer, 2020, 67, e28113.	1.5	5
59	Methodological advances in the discovery of novel neuroblastoma therapeutics. Expert Opinion on Drug Discovery, 2021, , 1-13.	5.0	5
60	Intratumoral immunosuppression profiles in 11qâ€deleted neuroblastomas provide new potential therapeutic targets. Molecular Oncology, 2021, 15, 364-380.	4.6	4
61	Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?. International Journal of Molecular Sciences, 2021, 22, 9815.	4.1	4
62	Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma. Journal of Neuroimmunology, 2016, 297, 98-102.	2.3	3
63	Postrelapse Prognostic Factors in Nonmetastatic Osteosarcoma. Journal of Pediatric Hematology/Oncology, 2016, 38, 176-181.	0.6	2
64	Precision medicine in relapsed or refractory pediatric solid tumors: a collaborative Spanish initiative. Translational Medicine Communications, 2019, 4, .	1.4	2
65	Immunohistochemical evaluation of a novel clone of monoclonal anti-MYCN antibody B8.4B in neuroblastic tumours: a correlation with MYCN gene status. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 277-278.	2.8	1
66	HG-128BO25041 - A PHASE II OPEN-LABEL, RANDOMIZED, MULTI CENTRE COMPARATIVE STUDY OF BEVACIZUMAB BASED THERAPY IN PAEDIATRIC PATIENTS WITH NEWLY DIAGNOSED SUPRATENTORIAL, INFRATENTORIAL CEREBELLAR, OR PEDUNCULAR HIGH GRADE GLIOMA. Neuro-Oncology, 2016, 18, iii77.4-iii77.	1.2	1
67	Next-Generation Sequencing Identifies Potential Actionable Targets in Paediatric Sarcomas. Journal of Personalized Medicine, 2021, 11, 268.	2.5	1
68	Retinoblastoma and mosaic 13q deletion: a case report. International Journal of Retina and Vitreous, 2021, 7, 50.	1.9	1
69	QUANTITATIVE APPROACH TO ASSIST NEUROBLASTOMA ASSESSMENT BY MEASURING I-123 mIBG UPTAKE IN SCINTIGRAPHIC IMAGES. Image Analysis and Stereology, 2015, 34, 135.	0.9	1
70	Germline variant in Ctcf links mental retardation to Wilms tumor predisposition. European Journal of Human Genetics, 2022, , .	2.8	1
71	HG-85INTER-OBSERVER AGREEMENT IN NEUROPATHOLOGICAL HGG DIAGNOSIS : EXPERIENCE OF THE PRE-RANDOMISATION CENTRAL REVIEW IN THE HERBY TRIAL. Neuro-Oncology, 2016, 18, iii68.1-iii68.	1.2	0
72	PNR-16DIAGNOSIS, MANAGEMENT AND OUTCOME OF CHILDREN WITH CENTRAL NERVOUS SYSTEM (CNS) PRIMITIVE NEUROECTODERMAL TUMORS (PNET) IN SPAIN: A STUDY FROM THE SPANISH NATIONAL PEDIATRIC ONCOLOGY & HEMATOLOGY SOCIETY (SEHOP). Neuro-Oncology, 2016, 18, iii9.5-iii10.	1.2	0

#	Article	IF	Citations
73	Early clinical trials in paediatric oncology in Spain: A nationwide perspective. Anales De PediatrÃa (English Edition), 2017, 87, 155-163.	0.2	0
74	Cancer in the first 18 months of life. Anales De PediatrÃa (English Edition), 2020, 93, 358-366.	0.2	0
75	ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non-metastaticextremity high-grade osteosarcoma: A merged analysis of an Italian (ISG) and a Spanish (GEIS) sarcoma groups' multicentric prospective trials.. Journal of Clinical Oncology, 2021, 39, 11527-11527.	1.6	0
76	Pediatric Neuroblastoma: Use of Hypermethylation of Apoptotic Genes as a Prognostic Factor. Pediatric Cancer, 2013, , 3-10.	0.0	0
77	Low- and Intermediate-Risk Neuroblastoma. , 2020, , 205-212.		0
78	Neuroblastoma in Spain: Linking the national clinical database and epidemiological registries â€“ A study by the Joint Action on Rare Cancers. Cancer Epidemiology, 2022, 78, 102145.	1.9	0